Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients.
Carol J FarhangfarGregory T ScarolaVictoria A MorrisFarhang FarhangfarKathryn DumasJames SymanowskiJimmy J HwangKathryn F MilehamDaniel R CarrizosaR Wendel NaumannChad LivasyEdward S KimDerek RaghavanPublished in: JCO clinical cancer informatics (2022)
Integrating CGP into clinical workflow with decision support tools, trial matching, and management of patient costs led to increased use of MP by physicians with all levels of experience, enhanced clinical trial accrual, and has the potential to reduce disparities in MP.
Keyphrases
- clinical trial
- phase ii
- study protocol
- phase iii
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- primary care
- prognostic factors
- open label
- case report
- randomized controlled trial
- peritoneal dialysis
- single cell
- healthcare
- double blind
- patient reported outcomes
- risk assessment
- patient reported
- drug delivery
- placebo controlled
- climate change